Take a fresh look at your lifestyle.

China allows COVID boosters of different technologies than primary shots

China allows COVID boosters of different technologies than primary shots © Reuters. FILE PHOTO: A woman holds a small bottle labeled with a “Coronavirus COVID-19 Vaccine” sticker and a medical syringe in front of displayed China flag in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo

BEIJING (Reuters) – China is giving COVID-19 booster vaccines using technologies different from the initial injections, in an effort to improve immunisation strategies amid concerns that its most-used jabs appeared to be weaker against variants such as Omicron.

Boosting population immunity could be crucial to preparing China to eventually reopen its borders and pivot from its “dynamic zero” strategy, which involves travel curbs and mass testing following dozens of local infections. Experts are watching whether combined Chinese doses would lead to higher effectiveness.

Adults injected with a vaccine developed by Sinopharm or Sinovac at least six month earlier can now receive their booster doses with a vaccines using different technologies, produced by CanSino Biologics (CanSinoBIO) or a unit of Chongqing Zhifei Biological Products, National Health Commission official Wu Liangyou said on Saturday.

Around one-third of China’s 1.4 billion people had received boosters using vaccines of the same technologies as their primary doses as of Feb. 7.

Data showed that boosters of either the same or different technologies as primary vaccinations can improve immunity, Wu told a news briefing. He did not contrast the two approaches.

A small-sample Hong Kong research showed that Sinovac’s CoronaVac shot, boosted with a third dose about two to five months after the second, failed to produce neutralising antibody responses to Omicron in most recipients.

The Sinovac booster-triggered antibody response was also weaker against Delta than a CanSinoBIO booster in a clinical trial.

Tested against Omicron in a Chinese study, a third BBIBP-CorV shot produced by Sinopharm elicited lower antibody level than a booster of Zhifei’s vaccine in those who already received two BBIBP-CorV shot.

Among close contacts of infected people in an earlier Omicron outbreak in Chinese cities of Tianjin and Anyang, receiving a booster reduced Omicron breakthrough infection rate more than threefold compared with the primary vaccination, said Shao Yiming, who is on an expert team for China’s COVID vaccine development work group, at Saturday’s news briefing.

Shao did not provide complete data or specify which boosters were analysed for the readings.

Products from Sinopharm and Sinovac approved in China are inactivated vaccines that contain inactivated or “killed” coronavirus. Zhifei’s vaccine contains parts of the coronavirus protein, while the CanSinoBIO shot uses a modified human cold virus to ferry genetic material from the coronavirus protein.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More